Published in Clin Nucl Med on June 09, 2017
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol (2014) 6.61
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Positron-emission tomography and assessment of cancer therapy. N Engl J Med (2006) 5.43
The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood (2016) 3.21
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Utility of FDG-PET scanning in lymphoma by WHO classification. Blood (2003) 1.69
Imaging in staging of malignant lymphoma: a systematic review. Blood (2007) 1.56
Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Radiology (2004) 1.54
Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med (2001) 1.46
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol (2009) 1.44
18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med (2005) 1.41
Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging (2003) 1.34
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica (2014) 1.31
Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology (2005) 1.17
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol (2008) 1.15
Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol (2005) 1.12
PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med (2006) 1.11
Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2006) 1.02
Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol (2004) 0.98
Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol (2006) 0.93
Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). Eur J Nucl Med Mol Imaging (2016) 0.92
Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med (2005) 0.89
Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma. Q J Nucl Med Mol Imaging (2010) 0.84
Clinical significance of post-treatment (18)F-fluorodeoxyglucose uptake in cervical lymph nodes in patients with diffuse large B-cell lymphoma. Eur Radiol (2016) 0.84
Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma. Radiol Clin North Am (2007) 0.83
Integrated FDG PET/CT: Utility and Applications in Clinical Oncology. Clin Med Oncol (2008) 0.81
Detection of bone marrow involvement in newly diagnosed post-transplant lymphoproliferative disorder: (18)F-fluorodeoxyglucose positron emission tomography/computed tomography versus bone marrow biopsy. Leuk Lymphoma (2016) 0.78
[The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma]. Med Clin (Barc) (2007) 0.77
Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise? Acta Radiol (2014) 0.76
The diagnostic radiology exam of the future: the law of unintended consequences meets the law of supply and demand. AJR Am J Roentgenol (2008) 2.05
Calculation of electron dose to target cells in a complex environment by Monte Carlo code "CELLDOSE". Eur J Nucl Med Mol Imaging (2008) 1.97
Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging (2010) 1.85
Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging (2007) 1.81
Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun (2007) 1.72
Preoperative localization and radioguided parathyroid surgery. J Nucl Med (2003) 1.68
In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol (2007) 1.67
Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging (2009) 1.64
Assessment of optimal virus-mediated growth factor gene delivery for human cutaneous wound healing enhancement. J Invest Dermatol (2008) 1.56
Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med (2003) 1.54
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant (2006) 1.53
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging (2011) 1.53
18F-FDG PET/CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging (2013) 1.49
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging (2012) 1.44
Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. Eur J Nucl Med Mol Imaging (2008) 1.42
Sentinel lymph node biopsy in differentiated thyroid cancer: standard of care or experimental tool? Nucl Med Commun (2006) 1.41
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol (2007) 1.39
Allogeneic hematopoietic stem cell transplantation in patients 50 years of age and older. Haematologica (2002) 1.39
Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol (2007) 1.35
Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med (2013) 1.34
Prevalence of antibodies to Toxoplasma gondii and intestinal parasites in stray, farm and household cats in Spain. Vet Parasitol (2004) 1.33
Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol (2010) 1.32
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2012) 1.28
Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol (2008) 1.24
2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging (2009) 1.24
An in vivo model of wound healing in genetically modified skin-humanized mice. J Invest Dermatol (2004) 1.22
Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun (2004) 1.21
Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol (2010) 1.20
FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. World J Clin Oncol (2011) 1.19
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl Med Commun (2007) 1.19
Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med (2012) 1.17
Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med (2013) 1.16
68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol (2011) 1.14
Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica (2010) 1.13
Microbial targeting of 99mTc-labeled recombinant human beta-defensin-3 in an animal model of infection: a feasibility pilot study. J Nucl Med (2009) 1.13
Magnetic resonance imaging in patients with cardiac pacemakers: era of "MR Conditional" designs. J Cardiovasc Magn Reson (2011) 1.12
Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging (2011) 1.11
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol (2007) 1.09
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun (2009) 1.09
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun (2005) 1.06
What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging (2007) 1.06
Radionuclide gastroesophageal motor studies. J Nucl Med (2004) 1.06
PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol (2011) 1.04
Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation (2004) 1.04
Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood (2007) 1.03
The sentinel node procedure in breast cancer: nuclear medicine as the starting point. J Nucl Med (2011) 1.03
Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol (2010) 1.02
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.01
Parathyroid scintigraphy: when, how, and why? A concise systematic review. Clin Nucl Med (2012) 1.01
Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother (2006) 1.01
Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol (2010) 1.01
Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol (2006) 1.00
Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging (2009) 1.00
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol (2007) 1.00
Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients: are there sources of benign secretion? A speculative short review. Nucl Med Commun (2010) 0.99
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging (2008) 0.99
18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging (2005) 0.98
Evaluation of the efficacy of a topically administered combination of imidacloprid and permethrin against Phlebotomus perniciosus in dog. Vet Parasitol (2006) 0.98
Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.98
Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother (2004) 0.98
A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides. FASEB J (2004) 0.98
Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-beta. Circulation (2003) 0.97
A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood (2010) 0.97
Radionuclide evaluation of the lower gastrointestinal tract. J Nucl Med (2008) 0.97
Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med (2007) 0.96
68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. J Nucl Med (2010) 0.96
68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun (2007) 0.96
Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Cancer (2009) 0.95
Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med (2013) 0.95
Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother (2008) 0.95
Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science? Eur J Nucl Med Mol Imaging (2007) 0.95
Low pleural fluid-to-serum glucose gradient indicates pleuroperitoneal communication in peritoneal dialysis patients: presentation of two cases and a review of the literature. Nephrol Dial Transplant (2011) 0.95
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med (2016) 0.94
The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med (2013) 0.94
Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET. Nucl Med Commun (2007) 0.94
Survey of intestinal parasites in stray dogs in the Madrid area and comparison of the efficacy of three anthelmintics in naturally infected dogs. Parasitol Res (2006) 0.94
Features of papillary thyroid carcinoma in patients older than 75 years. Updates Surg (2011) 0.94
Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother (2007) 0.94
The prevalence of incidental findings at cardiac MRI. Open Cardiovasc Med J (2008) 0.93
Molecular imaging of pulmonary nodules. AJR Am J Roentgenol (2014) 0.93
The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol (2003) 0.92
Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer. Am J Clin Oncol (2011) 0.92
18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. Eur J Radiol (2010) 0.92
Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging. Biomed Pharmacother (2012) 0.92
PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging (2008) 0.91
Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging (2013) 0.91
(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2010) 0.91
Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. Endocrine (2013) 0.91
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. Clin Nucl Med (2013) 0.90